NIAID- VRC- Evaluating mRNA Vaccine Candidates and Capability Development

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: BARRY  GAUSE
Organization: LEIDOS BIOMEDICAL RESEARCH, INC.
Fiscal Year: 2022
Award: $1,527,328
Funding agency: National Institute of Allergy and Infectious Diseases

The Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health, was established to facilitate research in vaccine development and is dedicated to improving global human health through the rigorous pursuit of effective vaccines and treatments for human diseases. One of the key components of the VRC's mission involves the rapid advancement of promising candidates from the laboratory to the clinic. Meeting this mission necessitates the development and manufacturing of vaccines for toxicology, and Phase 1 clinical trials.

Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Clinic><Clinical Evaluation><Clinical Testing><Development><Early-Stage Clinical Trials><Enterovirus><Filoviridae><Filovirus><Grippe><HIV><Health><Human><Human Immunodeficiency Viruses><Influenza><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><Mission><Modern Man><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Phase 1 Clinical Trials><Phase I Clinical Trials><Preclinical Testing><RNA vaccine><RNA-based vaccine><Research><Research Support><Toxicology><United States National Institutes of Health><Vaccine Research><Vaccines><Virus-HIV><clinical test><develop a vaccine><develop vaccines><development of a vaccine><developmental><human disease><improved><mRNA vaccine><mRNA-based vaccine><meetings><phase I protocol><pre-clinical testing><prevent><preventing><research clinical testing><vaccine candidate><vaccine development>